An interventional study of reflective material in Premature, Phototherapy and Neonatal Intensive Care Unit, sponsored by Kubra Nur Kabakcı Sarıdağ. Completed at 1 site in Turkey (Türkiye). Open to participants aged 36 Weeks to 42 Weeks. Per ClinicalTrials.gov, last updated 2026-09-14.
Sponsored by Kubra Nur Kabakcı Sarıdağ · Not applicable, Interventional, and Supportive care
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 247 studies in Premature Birth with a site in Turkey — 44 open to participants now, 49 under way, none of them phase 3. Premature Birth · Turkey.
Among the 247 studies in Premature Birth with a site in Turkey, this one is the 58th largest by enrollment of the 197 interventional ones that give a count, is one of 34 that started in 2024, is one of 192 with no phase, and was the 209th registered.
2,557 studies on the registry are indexed under Premature Birth; 504 are open to participants now.
Browse Premature Birth studies →44 of the 247 studies in Premature Birth with a site in Turkey are open now. Recruiting first, the newest first:
Mersin University · Sites in Turkey
Ages 32 wk–37 mo
Kubra Nur Kabakcı Sarıdağ · Sites in Turkey
Ages 32 wk–37 wk · Healthy volunteers
Gazi University · Sites in Turkey
Ages 3 mo–12 mo
Ataturk University · Sites in Turkey
Ages 28 wk–32 wk · Healthy volunteers
Uludag University · Sites in Turkey
Ages 0 hrs–6 hrs
A study can be open while its sites in Turkey have not opened yet or have stopped. Only those recruiting at a site in Turkey →
Of the 318 Premature Birth studies recruiting now, 88 (28%) set no upper age limit and 226 (71%) stop at 75 or younger; 243 take children under 18; 104 take healthy volunteers.
This study: 36 Weeks to 42 Weeks · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
247 studies; the count open now beside each. This study's row is marked.
First in 2009; this study’s year is marked. 34 started in 2024.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 81 is close to the median of 84 across 1,670 interventional studies indexed under Premature Birth.
Median enrollment 64 across the 197 interventional studies, 90 across the 49 observational. Of the 169 that completed or were terminated, 1 (1%) have results posted.
This tab as a report to print or save as PDF → With an account.
None of the 247 has an industry lead sponsor. The 10 most frequent:
Kubra Nur Kabakcı Sarıdağ is the lead sponsor of 2 studies on the registry; 1 is open to participants now.
Kubra Nur Kabakcı Sarıdağ has 2 studies filed under Premature Birth — fewer than ten, so there is no comparison to draw.
9 of the studies in Premature Birth with a site in Turkey that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07864298Uskudar UniversityCohesive Bandage Fixation of Pulse Oximeter Probes and Skin Condition in Preterm Neonates | 2026-11 |
| NCT07525167Konya City HospitalEarly Prediction of Bronchopulmonary Dysplasia in Preterm Infants Using Clinical Data | 2026-12-01 |
| NCT06823115Indiana UniversityAssessment of Worldwide Acute Kidney Injury Epidemiology in Neonates 2.0 | 2027-01 |
| NCT07917871Marmara UniversityEffects of Environmental Comfort and Oral Motor Stimulation on Comfort and Oral Feeding Readiness in Preterm Infants | 2027-01-01 |
| NCT07350018Uludag UniversityCalfactant vs Poractant Alfa Using a Less Invasive Technique in Preterm Infants With Respiratory Distress Syndrome | 2027-02-20 |
Add all 9 to your calendar (.ics) → With an account.
Among the 247 studies in Premature Birth with a site in Turkey, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Background: Indirect hyperbilirubinemia (IHB) is a common neonatal condition, affecting over 60% of term and 80% of preterm infants. Phototherapy is the most widely used, safe, and non-invasive treatment; however, scattering of phototherapy light decreases treatment efficacy, prolongs therapy duration, and increases the risk of side effects. Reflective materials have been suggested to enhance phototherapy effectiveness, yet studies comparing different reflector types remain limited.
Aim: This study aims to compare the effects of using reflective materials (white cloth or aluminum foil) during phototherapy on total serum bilirubin levels and phototherapy duration, in neonates with physiological IHB.
Methods: This single-center, single-blind, randomized controlled trial will be conducted at Ankara University Faculty of Medicine, Cebeci Neonatal Intensive Care Unit. A total of 81 neonates with gestational age 35-42 weeks and total serum bilirubin levels of 15-20 mg/dl will be randomly assigned into three groups: (1) phototherapy with white cloth reflectors, (2) phototherapy with aluminum foil reflectors, and (3) standard phototherapy (control). Data will be collected using an Introductory Information Form and Daily Follow-up Chart. Statistical analyses will include parametric and non-parametric tests based on distribution assumptions, with significance set at p\<0.05.
Expected Results: It is hypothesized that the use of reflective materials will result in faster reduction of total serum bilirubin and shorter phototherapy compared with standard phototherapy.
Conclusion: The study will provide evidence on the comparative effectiveness of two low-cost reflector materials in enhancing phototherapy outcomes, potentially offering a practical and efficient strategy for neonatal hyperbilirubinemia management.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Bilirubin
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The three sides of the incubator will be covered with a cardboard panel, cut to fit the incubator dimensions, lined with white linen cloth on the inner surface (length 88 cm, width 47 cm, height 34 cm).
Other: reflective material
The incubators will be enclosed by a panel covered with aluminum foil on three sides (long side 88 cm, short side 47 cm, height 34 cm).
Other: reflective material
Infants will receive treatment in accordance with standard phototherapy practice.
When receiving phototherapy treatment in groups, reflective materials (aluminum foil-coated sheet or white sheet-covered sheet) were placed in the incubators.
Change in Total Serum Bilirubin Level
The difference in total serum bilirubin concentration measured at baseline (before phototherapy), at the 4th hour, and at the last measurement during phototherapy, expressed in mg/dL.
Time frame: At baseline (prior to phototherapy), 4 hours after initiation, and at the final assessment before discontinuation of phototherapy (up to 24 hours)
Duration of Phototherapy
Total duration of phototherapy received by each infant, recorded in hours.
Time frame: Measured once at completion of phototherapy (up to 24 hours after initiation)
Plan to share: No — Individual participant data will not be shared.
No publications or documents are linked to this record.
Ran from Dec 2024 to primary completion in Jun 2025, 5 months.
Of 746 non-industry interventional studies with no phase under Premature Birth, half reached primary completion within 23 months of starting (the median), counting those still running; a quarter within 12 and three quarters within 47. This study's 5 months is below that.
Counting every sponsor, half of 764 studies reached it within 24 months; a quarter within 12 and three quarters within 47.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Kubra Nur Kabakcı Sarıdağ